Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : son of T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (57)	8/18/1999 9:39:00 AM
From: biowa	Respond to of 673

DAK, And the little boy who cried (or didn't cry) "wolf." Remember its management, management, management and the street may be getting tired of Robinson's lack of veracity. biowa

To: LLCF who wrote (57)	8/18/1999 10:17:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 673

Low margins and the cost of sales is high. Moreover, the products have limited demand. Somewhere in the old T/FIF thread, I almost upchucked when Robinson said that the company would be profitable in '99. Train wreck in slow motion.........one can clearly see what's happening (dilution) if they just take off the rose-colored glasses. Easy call, overall, in '96. Easy call, regarding profitability in '99, the second after if emerged from Robinson's mouth. To put it bluntly..... if the CEO had been replaced in '96 with any one of ten candidates that I could have suggested, the company would be in much better shape now. Before all of the lurkers pop up, consider this..... how many companies have I criticized that have gone on to thrive? How many companies have I gotten behind that have failed to thrive? (yes, there have been some...... this is biotech, after all..... but look at the frequency of my successes relative to others) This all sounds very egotistical. The intent of the T/FIF threads is to chase away dogma and to teach various methods for investing in biotech. The sector as a whole has a terrible rep, but certain companies go to the sky. It's an issue of picking good business plans and thumbing your nose at "experts" who sell their vested interests. I hope, given that focus and my passion for the sector, that readers can take the ego out of this post and understand that I wish that I had been wrong. If you study carefully, one can put together separate baskets of companies that will outperform and underperform. Simple claim, and the documentation is in the m.i.s and SI archives. Let's hope things can turn around. Ligand used to be one of our flagship companies. I owned it until '96, and I invested in Allergan-LGND Retinoid Therapeutics. Great concept, terrible execution.